AKESO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49 HKD | 0.00% |
|
+0.62% | +5.60% |
ETFs positioned on Akeso, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.57% | 4 M€ | -27.92% | ||
| 0.44% | 2 M€ | -14.14% | ||
| 0.03% | 441 M€ | +7.05% | - | |
| 0.03% | 2,808 M€ | +8.54% | - | |
| 0.03% | 149 M€ | +5.36% | - | |
| 0.03% | 117 M€ | +3.00% | - | |
| 0.03% | 4 M€ | -4.41% | - | |
| 0.01% | 31 M€ | +5.93% | - | |
| 0.00% | 389 M€ | +7.96% | - | |
| 0.00% | 34 M€ | +3.24% | - | |
| 0.00% | 7 M€ | +3.48% | - | |
| 0.00% | 34 M€ | +6.71% | - | |
| 0.00% | 39 M€ | +4.35% | - | |
| 0.00% | 302 M€ | +5.32% | - | |
| 0.00% | 108 M€ | +3.05% | - | |
| 0.00% | 17 M€ | +1.96% | - | |
| 0.00% | 15 M€ | +12.19% | ||
| 0.00% | 52 M€ | +0.32% | - | |
| 0.00% | 8 M€ | -0.02% | - |
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.18
CNY
Average target price
55.44
CNY
Spread / Average Target
+22.70%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.60% | 5.43B | |
| +8.88% | 105B | |
| -0.68% | 104B | |
| +5.79% | 22.94B | |
| -12.25% | 22.34B | |
| -7.01% | 19.25B | |
| -37.08% | 17.08B | |
| -9.19% | 16.96B | |
| +7.89% | 14.16B | |
| +37.66% | 12.63B |
- Stock Market
- Equities
- 9926 Stock
- Funds and ETFs Akeso, Inc.